Gradientech

Fighting antibiotic resistance

  • CEO: Sara Thorslund
  • First investment year: 2011
  • Fund: Eastern Mid Sweden
  • Business sector: Life Science

Gradientech provides precision assays and software solutions for high-quality analysis of cell behavior in response to gradients of signalling molecules. Driven by the increased global prevalence of antibiotic resistance, Gradientech is developing its microfluidic platform QuickMIC - the most rapid IVD system for antibiotic susceptibility testing of sepsis patients.